Search
Oct 24
Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic diseases
CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key...